PARATEK PHARMACEUTICALS INC (PRTK)
US6993743029 - Common Stock
We assign a fundamental rating of 2 out of 10 to PRTK. PRTK was compared to 198 industry peers in the Pharmaceuticals industry. Both the profitability and financial health of PRTK have multiple concerns. PRTK is valued quite expensively, but it does show have an excellent growth rating.
1. Profitability
1.1 Basic Checks
PRTK had negative earnings in the past year.
PRTK had a negative operating cash flow in the past year.
PRTK had negative earnings in each of the past 5 years.
In the past 5 years PRTK always reported negative operating cash flow.
1.2 Ratios
PRTK has negative profitability rations, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | N/A | ||
| ROE | N/A | ||
| ROIC | N/A |
ROA(3y)N/A
ROA(5y)N/A
ROE(3y)N/A
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
1.3 Margins
PRTK has a better Gross Margin (85.71%) than 89.57% of its industry peers.
In the last couple of years the Gross Margin of PRTK has grown nicely.
PRTK does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 85.71% |
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3Y2.73%
GM growth 5YN/A
2. Health
2.1 Basic Checks
PRTK does not have a ROIC to compare to the WACC, probably because it is not profitable.
Compared to 1 year ago, PRTK has more shares outstanding
The number of shares outstanding for PRTK has been increased compared to 5 years ago.
PRTK has a worse debt/assets ratio than last year.
2.2 Solvency
Based on the Altman-Z score of -9.64, we must say that PRTK is in the distress zone and has some risk of bankruptcy.
PRTK's Altman-Z score of -9.64 is on the low side compared to the rest of the industry. PRTK is outperformed by 75.83% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | N/A | ||
| Altman-Z | -9.64 |
ROIC/WACCN/A
WACC7.65%
2.3 Liquidity
A Current Ratio of 0.52 indicates that PRTK may have some problems paying its short term obligations.
PRTK has a Current ratio of 0.52. This is amonst the worse of the industry: PRTK underperforms 92.42% of its industry peers.
PRTK has a Quick Ratio of 0.52. This is a bad value and indicates that PRTK is not financially healthy enough and could expect problems in meeting its short term obligations.
PRTK has a worse Quick ratio (0.46) than 92.42% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 0.52 | ||
| Quick Ratio | 0.46 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an impressive 35.67% over the past year.
PRTK shows a strong growth in Revenue. In the last year, the Revenue has grown by 59.83%.
The Revenue has been growing by 66.25% on average over the past years. This is a very strong growth!
EPS 1Y (TTM)35.67%
EPS 3YN/A
EPS 5YN/A
EPS growth Q2Q24.24%
Revenue 1Y (TTM)59.83%
Revenue growth 3Y113.19%
Revenue growth 5Y66.25%
Revenue growth Q2Q34.94%
3.2 Future
PRTK is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 31.93% yearly.
Based on estimates for the next years, PRTK will show a very strong growth in Revenue. The Revenue will grow by 22.58% on average per year.
EPS Next Y32.14%
EPS Next 2Y41.42%
EPS Next 3Y26.53%
EPS Next 5Y31.93%
Revenue Next Year9.93%
Revenue Next 2Y25.23%
Revenue Next 3Y14.33%
Revenue Next 5Y22.58%
3.3 Evolution
The estimated forward Revenue growth is still strong, although it is decreasing when compared to the stronger growth in the past years.
4. Valuation
4.1 Price/Earnings Ratio
PRTK reported negative earnings for the last year, which makes the Price/Earnings Ratio negative.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A |
4.2 Price Multiples
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | N/A | ||
| EV/EBITDA | N/A |
4.3 Compensation for Growth
PRTK's earnings are expected to grow with 26.53% in the coming years. This may justify a more expensive valuation.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y41.42%
EPS Next 3Y26.53%
5. Dividend
5.1 Amount
No dividends for PRTK!.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
PARATEK PHARMACEUTICALS INC
NASDAQ:PRTK (9/20/2023, 7:00:00 PM)
After market: 2.23 0 (0%)2.23
+0.04 (+1.83%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryPharmaceuticals
Earnings (Last)
Earnings (Next)
Inst Owners
Inst Owner Change
Ins Owners
Ins Owner Change
Market Cap127.82M
Analysts
Price Target
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | N/A |
Dividend Growth(5Y)
DP
Div Incr Years
Div Non Decr Years
Ex-Date
Surprises & Revisions
EPS beat(2)
Avg EPS beat(2)
Min EPS beat(2)
Max EPS beat(2)
EPS beat(4)
Avg EPS beat(4)
Min EPS beat(4)
Max EPS beat(4)
EPS beat(8)
Avg EPS beat(8)
EPS beat(12)
Avg EPS beat(12)
EPS beat(16)
Avg EPS beat(16)
Revenue beat(2)
Avg Revenue beat(2)
Min Revenue beat(2)
Max Revenue beat(2)
Revenue beat(4)
Avg Revenue beat(4)
Min Revenue beat(4)
Max Revenue beat(4)
Revenue beat(8)
Avg Revenue beat(8)
Revenue beat(12)
Avg Revenue beat(12)
Revenue beat(16)
Avg Revenue beat(16)
PT rev (1m)
PT rev (3m)
EPS NQ rev (1m)
EPS NQ rev (3m)
EPS NY rev (1m)
EPS NY rev (3m)
Revenue NQ rev (1m)
Revenue NQ rev (3m)
Revenue NY rev (1m)
Revenue NY rev (3m)
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | N/A | ||
| Fwd PE | N/A | ||
| P/S | |||
| P/FCF | |||
| P/OCF | |||
| P/B | |||
| P/tB | |||
| EV/EBITDA |
EPS(TTM)
EY
EPS(NY)
Fwd EY
FCF(TTM)
FCFY
OCF(TTM)
OCFY
SpS
BVpS
TBVpS
PEG (NY)N/A
PEG (5Y)N/A
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | N/A | ||
| ROE | N/A | ||
| ROCE | |||
| ROIC | |||
| ROICexc | |||
| ROICexgc | |||
| OM | N/A | ||
| PM (TTM) | N/A | ||
| GM | 85.71% | ||
| FCFM |
ROA(3y)
ROA(5y)
ROE(3y)
ROE(5y)
ROIC(3y)
ROIC(5y)
ROICexc(3y)
ROICexc(5y)
ROICexgc(3y)
ROICexgc(5y)
ROCE(3y)
ROCE(5y)
ROICexcg growth 3Y
ROICexcg growth 5Y
ROICexc growth 3Y
ROICexc growth 5Y
OM growth 3Y
OM growth 5Y
PM growth 3Y
PM growth 5Y
GM growth 3Y
GM growth 5Y
F-Score
Asset Turnover1.21
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | N/A | ||
| Debt/FCF | |||
| Debt/EBITDA | |||
| Cap/Depr | |||
| Cap/Sales | |||
| Interest Coverage | |||
| Cash Conversion | |||
| Profit Quality | |||
| Current Ratio | 0.52 | ||
| Quick Ratio | 0.46 | ||
| Altman-Z |
F-Score
WACC
ROIC/WACC
Cap/Depr(3y)
Cap/Depr(5y)
Cap/Sales(3y)
Cap/Sales(5y)
Profit Quality(3y)
Profit Quality(5y)
Growth
EPS 1Y (TTM)35.67%
EPS 3YN/A
EPS 5Y
EPS growth Q2Q
EPS Next Y32.14%
EPS Next 2Y
EPS Next 3Y
EPS Next 5Y
Revenue 1Y (TTM)59.83%
Revenue growth 3Y113.19%
Revenue growth 5Y
Revenue growth Q2Q
Revenue Next Year
Revenue Next 2Y
Revenue Next 3Y
Revenue Next 5Y
EBIT growth 1Y
EBIT growth 3Y
EBIT growth 5Y
EBIT Next Year
EBIT Next 3Y
EBIT Next 5Y
FCF growth 1Y
FCF growth 3Y
FCF growth 5Y
OCF growth 1Y
OCF growth 3Y
OCF growth 5Y